HilleVax, Inc. Profile Avatar - Palmy Investing

HilleVax, Inc.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis c…

Biotechnology
US, Boston [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

HilleVax, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of HLVX's Analysis
CIK: 1888012 CUSIP: 43157M102 ISIN: US43157M1027 LEI: - UEI: -
Secondary Listings
HLVX has no secondary listings inside our databases.